Articles & practical guides
Practical, evidence-anchored articles on the questions people actually ask about GLP-1 medications, peptides, and obesity therapy. Head-to-head comparisons, side-effect timelines, prevention strategies, and the long-term considerations that don't fit neatly into a peptide page.
How this section works
The articles below are written to answer specific questions — the ones people actually search for when they're navigating GLP-1 therapy or peptide research. Each article includes a 60-second TL;DR at the top, structured sections with the substantive answer, key takeaways, and an FAQ. We cite the underlying research throughout and link to the peptide pages where the deeper evidence lives.
If you want the comprehensive evidence base on a specific compound, the peptide pages are the right place. If you want a calibrated read on a specific contested claim, the Evidence vs Myth section is the right place. This Articles section is for the practical, "how do I actually navigate this?" questions.
Head-to-head comparisons · 3 articles
Direct comparisons between commonly-paired peptides and drugs — what the evidence shows about which is right for whom.
Semaglutide vs Tirzepatide for Weight Loss: A 2026 Comparison
The most-asked comparison in modern obesity medicine. We work through the head-to-head trial data, the dual-agonist mechanism that makes tirzepatide deeper, the cardiovascular evidence semaglutide has and tirzepatide doesn't yet — and which one fits which patient.
Read articleMounjaro vs Zepbound: Are They the Same Drug?
Two brand names, four-figure marketing budgets behind each — and the same molecule inside. Here's why one drug has two names, what's actually different between them, and what it means for cost, coverage, and clinical use.
Read articleSemaglutide vs Ozempic vs Wegovy vs Rybelsus: Why Four Names for One Drug?
All four names refer to semaglutide — the same molecule, manufactured by Novo Nordisk. The differences are in dose, indication, formulation, and brand. Here's what each name actually represents and how to navigate the choice when your doctor mentions one specifically.
Read articlePractical guides · 4 articles
Practical, evidence-based guides for the questions people actually ask about peptide and obesity-medicine therapy.
How to Avoid Muscle Loss on GLP-1 Medications
About 25-40% of GLP-1-driven weight loss is lean mass — and that fact has driven both legitimate concern and substantial overstatement. Here's what the data actually shows, who's at the highest risk, and the evidence-based interventions that meaningfully reduce muscle loss without slowing fat loss.
Read articleBPC-157 Dosing for Tendon Injuries: What the Research Actually Suggests
The most-asked practical question about BPC-157. Here's what the preclinical literature suggests about dosing, what the athletic and biohacker communities are actually doing, the regulatory considerations that shape availability, and the honest gap between rodent-protocol data and validated human protocols.
Read articleAre Research Peptides Legal in the United States in 2026?
The legal status of research peptides is more nuanced than either 'totally legal' or 'totally illegal' framings suggest. Here's what the actual federal framework looks like, what the 'research use only' label does and doesn't mean, and where the gray areas live.
Read articleBest Peptide Stacks for Fat Loss: A 2026 Evidence-Based Review
Five peptide stacks ranked by how much actual human evidence supports the combination, what each accomplishes mechanistically, and where they fit in 2026's evolving obesity-pharmacology landscape. Plus the honest verdict on which combinations are validated, which are theoretical, and which are mostly community marketing.
Read articleSide effects & safety · 1 article
Honest coverage of side effects, what's normal vs. concerning, and how to navigate them.
Lifestyle & long-term · 2 articles
Long-term and lifestyle considerations alongside peptide and GLP-1 therapy.
Ozempic Face: What Causes It and How to Prevent It
The term started as social-media shorthand and has become a defining concern for GLP-1 patients. Here's the actual biology behind facial volume loss during rapid weight loss, who's most affected, and the evidence-based prevention strategies that work.
Read articleWhat to Eat While on Semaglutide: A Practical Nutrition Guide
GLP-1 medications change appetite, satiety, and food tolerance in ways that make nutrition strategy more important — not less. Here's a practical framework for eating well during semaglutide therapy: protein-first, foods that work, foods that don't, hydration, and the long-term habits that determine outcomes.
Read articleFor deeper reading
The Articles section is the practical layer; the peptide pages are the per-compound research base; the Stacks section covers theoretical combinations; the Evidence vs Myth section addresses specific contested claims; the GLP-1 Hub is the most-developed evidence-grade material on metabolic peptides; and Emerging Peptides tracks the frontier.